Skip to main content

Neuropathy clinical trials at UCSF
2 in progress, 0 open to eligible people

  • Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

    Sorry, in progress, not accepting new patients

    The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is considered experimental; that means this combination has not been approved by the FDA. The funding for this study is provided by Eisai Inc., the maker of eribulin.

    San Francisco, California

  • Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP

    Sorry, not currently recruiting here

    A randomized, open‑label, prospective, multicenter study designed to investigate 2 dose regimens in pediatric subjects 2 to < 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

    San Francisco, California and other locations